IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

if re Application of: Van Den Berghe, Greta

Application No.: 09/853,193

Group Art Unit: 1646

Filed: May 11, 2001

Examiner: Kam, C.

Confirmation No: 5893

For: Methods and Preparations For Curing Clinically Ill Patients

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

- 1. US Patent No. 6,277,819
- 2. WO 03/028626

Express Mail Label No. EV 409530457 US Attorney Docket No. 6296.204-US Serial No. 09/853,193

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This supplemental information disclosure statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this supplemental information disclosure statement is

the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: January 26, 2004

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton, NJ 08540 (609) 987-5800

Use the following customer number for all correspondence regarding this application

23650

PATENT TRADEMARK OFFICE

23650

PATENT TRADEMARK OFFICE

FORM PTQ-1442- (Rev.) 32)	- Si		MENT OF COMMERCE TRADEMARK OFFICE	Atty. Docket No. 6296.204-US		Serial No. 09/853,193		
JAN 2 6 201	TOFORMATIC STATEMENT	ON DISCLOSUR BY APPLICAN	E T	Applicant Van Den Berghe, Greta				
JAN 2	Use several s	heets if necessary		Filing Date May 11, 2001		Group 1646		
THADELE !	BIK O		U.S. PATE	NT DOCUMENTS				
EXAMINER INITIAL	DOC	CUMENT	DATE	NABAR	CLASS	CLIDOT ACC	FILING DATE	
INTIAL	NUMBER 6,277,819		8-21-2001	NAME Efendic	CLASS 514	SUBCLASS 12	IF APPROPRIATE	
								···
	-							
		**						<u>_</u>
	-				-			
			<u> </u>		<u> </u>			
	FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION							
	İ	JMBER	DATE	COLINERAL	61.433			LATION
	03/028626		4-10-03	COUNTRY WO	CLASS	SUBCLASS	YES	NO
					_ +			
						/* /		<u> </u>
		<u></u>						
·							***	<u> </u>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
}					· · · · · · · · · · · · · · · · · · ·	·		
	 					·		
	<u> </u>						<u>-</u>	
ļ								
EXAMINER DATE CONSIDERED								
PVAMINDD I WILLE II.								

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.